Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Avalo Therapeutics, Inc. AVTX
$2.45
+$0.05 (2.08%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
34585310.00000000
-
week52high
7.42
-
week52low
1.41
-
Revenue
18051000
-
P/E TTM
-1
-
Beta
1.60242200
-
EPS
-4.72000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Outperform | Outperform | 03 мар 2022 г. |
| Jefferies | Hold | Buy | 03 мар 2022 г. |
| RBC Capital | Outperform | 24 сент 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Almenoff June Sherie | A | 410 | 410 | 30 дек 2022 г. |
| Persson Magnus | A | 2536 | 2536 | 30 дек 2022 г. |
| NEIL GARRY ARTHUR | A | 9220 | 2083 | 09 дек 2022 г. |
| Sullivan Christopher Ryan | A | 25000 | 25000 | 05 окт 2022 г. |
| NEIL GARRY ARTHUR | A | 75000 | 75000 | 05 окт 2022 г. |
| KAPLAN GILLA | A | 3080 | 3080 | 30 сент 2022 г. |
| Almenoff June Sherie | A | 605 | 605 | 30 сент 2022 г. |
| Persson Magnus | A | 3747 | 3747 | 30 сент 2022 г. |
| Persson Magnus | A | 26837 | 26837 | 30 июн 2022 г. |
| KAPLAN GILLA | A | 44115 | 44115 | 30 июн 2022 г. |
Новостная лента
Avalo to Present at the H.C. Wainwright Global Investment Conference
GlobeNewsWire
01 сент 2022 г. в 07:00
WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held September 12-14, 2022.
Avalo to Present at the 2022 Jefferies Healthcare Conference
GlobeNewsWire
02 июн 2022 г. в 07:30
WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 4:00 PM ET at the Marriott Marquis in New York, NY.